Now it's a $70-$80M company with not much of value, and very top heavy. Arbutus was top-heavy from the beginning but now is there any reason to have all these execs? The board of the directors is now essentially useless as they're a pre-clin company and need technical direction more than anything.

I wonder how much the golden handshakes will cost in terms of months of pre-clin runway? Significant no doubt.

Dirk called it a retirement plan for old pharma execs [paraphrase], and I think he may have hit it on the head.